Alemtuzumab in multiple sclerosis: A retrospective analysis of occult hemorrhagic magnetic resonance imaging lesions and risk factors-Reference-Cited by-同舟云学术

Alemtuzumab in multiple sclerosis: A retrospective analysis of occult hemorrhagic magnetic resonance imaging lesions and risk factors

Published:2021-08-20 Issue:12 Volume:28 Page:4209-4213
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Bachmann Helen¹^ORCID,Cambron Melissa²,Casselman Jan W.²,Van Driessche Veroniek¹,Van Haute Eline¹,Van Hijfte Liesbeth¹,Kelderman Tim¹,Hemelsoet Dimitri¹,Laureys Guy¹

Affiliation:

1. Ghent University Hospital Ghent Belgium

2. Sint‐Jan Bruges Hospital Bruges Belgium

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.15054

Reference14 articles.

1. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

2. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use

3. Intracerebral haemorrhage during alemtuzumab administration

4. Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report

5. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications;European Journal of Medical Research;2024-06-25

2. Risk of secondary immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis;Frontiers in Neurology;2024-04-10

3. Alemtuzumab infusion-associated reactions and laboratory changes in patients with relapsing-remitting multiple sclerosis at baseline and first-year follow-up;Heliyon;2024-03

4. Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen;Multiple Sclerosis and Related Disorders;2022-10

5. Alemtuzumab induced hemodynamic change in relapsing multiple sclerosis occurs independent of corticosteroid premedication – a retrospective multicentre study;Multiple Sclerosis and Related Disorders;2022-07